Covidien divests specialty chemicals business
This article was originally published in The Gray Sheet
Executive SummaryDiversified device, medical supply and drug maker will divest its specialty chemicals business to an affiliate of New Mountain Capital LLC for $280 million under an agreement announced May 26. The division, which generated sales of $414 million in fiscal 2009, makes chemicals and related products for research and quality control labs, microelectronics, and for manufacturing in pharmaceutical, biotechnology and other industries. The sale is part of Covidien's strategy of selling off businesses outside the health care space since its spin-off from Tyco in 2007
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.